PL2720043T3 - Przeciwciała HMGB1 i anty-HMGB1 do prognozowania zaburzeń neurologicznych - Google Patents

Przeciwciała HMGB1 i anty-HMGB1 do prognozowania zaburzeń neurologicznych

Info

Publication number
PL2720043T3
PL2720043T3 PL14150638.6T PL14150638T PL2720043T3 PL 2720043 T3 PL2720043 T3 PL 2720043T3 PL 14150638 T PL14150638 T PL 14150638T PL 2720043 T3 PL2720043 T3 PL 2720043T3
Authority
PL
Poland
Prior art keywords
hmgb1
prognosis
neurological disorders
antibodies
hmgb1 antibodies
Prior art date
Application number
PL14150638.6T
Other languages
English (en)
Inventor
Marie-Lise Gougeon
Béatrice Poirier-Beaudouin
Valérie Seffer
Héla Saidi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2720043T3 publication Critical patent/PL2720043T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0033—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room
    • A61B5/004—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
    • A61B5/0042—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part for the brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4029—Detecting, measuring or recording for evaluating the nervous system for evaluating the peripheral nervous systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4058—Detecting, measuring or recording for evaluating the nervous system for evaluating the central nervous system
    • A61B5/4064—Evaluating the brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4058—Detecting, measuring or recording for evaluating the nervous system for evaluating the central nervous system
    • A61B5/407—Evaluating the spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4082—Diagnosing or monitoring movement diseases, e.g. Parkinson, Huntington or Tourette
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
    • A61B10/0045—Devices for taking samples of body liquids
    • A61B2010/0077—Cerebrospinal fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4 or KC
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Developmental Disabilities (AREA)
  • High Energy & Nuclear Physics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
PL14150638.6T 2010-03-10 2011-03-10 Przeciwciała HMGB1 i anty-HMGB1 do prognozowania zaburzeń neurologicznych PL2720043T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10290124.6A EP2365332B1 (en) 2010-03-10 2010-03-10 HMGB1 and anti-HMGB1 antibodies in HIV infected patients especially with neurological disorders

Publications (1)

Publication Number Publication Date
PL2720043T3 true PL2720043T3 (pl) 2016-09-30

Family

ID=42289547

Family Applications (3)

Application Number Title Priority Date Filing Date
PL10290124T PL2365332T3 (pl) 2010-03-10 2010-03-10 HMGB1 i przeciwciała anty-HMGB1 u pacjentów zakażonych HIV, zwłaszcza z zaburzeniami neurologicznymi
PL11710151T PL2545380T3 (pl) 2010-03-10 2011-03-10 Przeciwciała HMGB1 i anty-HMGB1 do prognozowania zaburzeń neurologicznych
PL14150638.6T PL2720043T3 (pl) 2010-03-10 2011-03-10 Przeciwciała HMGB1 i anty-HMGB1 do prognozowania zaburzeń neurologicznych

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL10290124T PL2365332T3 (pl) 2010-03-10 2010-03-10 HMGB1 i przeciwciała anty-HMGB1 u pacjentów zakażonych HIV, zwłaszcza z zaburzeniami neurologicznymi
PL11710151T PL2545380T3 (pl) 2010-03-10 2011-03-10 Przeciwciała HMGB1 i anty-HMGB1 do prognozowania zaburzeń neurologicznych

Country Status (11)

Country Link
US (3) US8728748B2 (pl)
EP (3) EP2365332B1 (pl)
JP (3) JP5703314B2 (pl)
KR (1) KR101972602B1 (pl)
CN (1) CN102884432B (pl)
CA (2) CA2944657C (pl)
DK (3) DK2365332T3 (pl)
ES (3) ES2413437T3 (pl)
PL (3) PL2365332T3 (pl)
PT (2) PT2365332E (pl)
WO (1) WO2011110650A2 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5710482B2 (ja) 2008-09-11 2015-04-30 アンスティテュ・パストゥール Ｈｍｇｂ１依存型誘発のｈｉｖ−１複製および持続の調節によるヒト免疫不全ウイルス感染の監視および阻害
PL2365332T3 (pl) 2010-03-10 2013-10-31 Pasteur Institut HMGB1 i przeciwciała anty-HMGB1 u pacjentów zakażonych HIV, zwłaszcza z zaburzeniami neurologicznymi
JP6249712B2 (ja) * 2013-10-09 2017-12-20 公益財団法人ヒューマンサイエンス振興財団 非傍腫瘍性急性脳炎患者の予後診断装置の作動方法
EP3067699A1 (en) * 2015-03-11 2016-09-14 Neuron Bio, S.A. Method for diagnosing alzheimer's disease
KR101734529B1 (ko) 2015-05-08 2017-05-11 건국대학교 산학협력단 패혈증 치료제의 스크리닝 방법 및 패혈증 치료용 약학 조성물
EP3165927A1 (en) 2015-11-03 2017-05-10 Institut Pasteur An assay to detect and quantitate specific antibodies for various redox forms of hmgb1
JP7107839B2 (ja) 2015-12-11 2022-07-27 ルプレヒト－カールス－ウニベルジテート ハイデルベルク Ｐｋｍ２モジュレーター及びｈｍｇｂ１の組合せ製剤
AR108688A1 (es) 2016-05-03 2018-09-19 Univ Arkansas Vector de vacuna de levadura que incluye polipéptidos inmunoestimuladores y antigénicos, métodos para su uso
JP2019152666A (ja) * 2018-03-02 2019-09-12 富士レビオ株式会社 ジカウイルスを検出する方法及びキット
CN111671895B (zh) * 2020-06-02 2022-03-08 江汉大学 抗PfHMGB1抗体在抗藻毒素试剂中的应用及抗藻毒素试剂
CN119775408B (zh) * 2025-03-12 2025-05-30 武汉伊莱瑞特生物科技股份有限公司 抗猴高迁移率族蛋白b1单克隆抗体、酶联免疫检测试剂盒及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5384240A (en) * 1992-11-25 1995-01-24 Akzo Nobel, N.V. Base dissociation assay
JP3472048B2 (ja) * 1995-10-09 2003-12-02 鐘淵化学工業株式会社 自己免疫疾患の診断薬
EP1577671A1 (en) * 1996-07-17 2005-09-21 Kaneka Corporation Diagnostic drugs for autoimmune diseases
US6541208B1 (en) * 1998-03-17 2003-04-01 University Of Maryland Biotechnology Institute Diagnostic method for distinguishing HIV-associated dementia from other forms of dementia
WO2000031536A2 (en) * 1998-11-23 2000-06-02 President And Fellows Of Harvard College Detecting structural or synthetic information about chemical compounds
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
GB0226251D0 (en) * 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
EP1668035A2 (en) 2003-09-11 2006-06-14 Critical Therapeutics, Inc. Monoclonal antibodies against hmgb1
CN1930474B (zh) * 2004-03-05 2012-07-04 普利玛食品株式会社 变应原的检测方法
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
CN101132811B (zh) * 2004-10-22 2012-05-30 米迪缪尼有限公司 抗hmgb1的高亲和力抗体及其用法
JP4682307B2 (ja) * 2005-11-17 2011-05-11 財団法人ヒューマンサイエンス振興財団 Ｈｉｖウイルス生産量測定マーカー及びその利用方法
US20070154955A1 (en) * 2005-12-30 2007-07-05 Industrial Technology Research Institute Method of diagnosing autoimmune polyglandular syndrome and kits thereof
CN101394860B (zh) * 2006-01-13 2013-05-29 范斯坦医药研究院 用丹参酮抑制炎性细胞因子产生
ATE504000T1 (de) * 2006-09-05 2011-04-15 Hvidovre Hospital Auf ip-10 basierende immunologische überwachung
CN101622364A (zh) * 2007-01-11 2010-01-06 杜克大学 监测hiv感染的方法
JP5710482B2 (ja) * 2008-09-11 2015-04-30 アンスティテュ・パストゥール Ｈｍｇｂ１依存型誘発のｈｉｖ−１複製および持続の調節によるヒト免疫不全ウイルス感染の監視および阻害
PL2365332T3 (pl) 2010-03-10 2013-10-31 Pasteur Institut HMGB1 i przeciwciała anty-HMGB1 u pacjentów zakażonych HIV, zwłaszcza z zaburzeniami neurologicznymi

Also Published As

Publication number Publication date
ES2532101T3 (es) 2015-03-24
CA2944657A1 (en) 2011-09-15
EP2720043B1 (en) 2016-01-20
JP2014224829A (ja) 2014-12-04
EP2720043A2 (en) 2014-04-16
CA2792506C (en) 2016-11-22
DK2720043T3 (en) 2016-03-29
DK2545380T3 (en) 2015-03-09
JP5703314B2 (ja) 2015-04-15
CA2792506A1 (en) 2011-09-15
US20130065221A1 (en) 2013-03-14
JP6196278B2 (ja) 2017-09-13
US8728748B2 (en) 2014-05-20
ES2413437T3 (es) 2013-07-16
US9164107B2 (en) 2015-10-20
US20140308755A1 (en) 2014-10-16
US9766254B2 (en) 2017-09-19
PT2365332E (pt) 2013-08-02
JP2013521511A (ja) 2013-06-10
CN102884432A (zh) 2013-01-16
US20160018418A1 (en) 2016-01-21
EP2720043A3 (en) 2014-08-20
EP2365332A1 (en) 2011-09-14
KR20130038832A (ko) 2013-04-18
EP2365332B1 (en) 2013-05-29
JP2016029397A (ja) 2016-03-03
WO2011110650A3 (en) 2012-02-02
PL2545380T3 (pl) 2015-06-30
EP2545380B1 (en) 2014-12-10
JP5851565B2 (ja) 2016-02-03
EP2545380A2 (en) 2013-01-16
ES2561610T3 (es) 2016-02-29
WO2011110650A2 (en) 2011-09-15
DK2365332T3 (da) 2013-08-26
KR101972602B1 (ko) 2019-04-25
CA2944657C (en) 2018-10-02
PL2365332T3 (pl) 2013-10-31
PT2545380E (pt) 2015-03-16
CN102884432B (zh) 2016-01-13

Similar Documents

Publication Publication Date Title
PL2545380T3 (pl) Przeciwciała HMGB1 i anty-HMGB1 do prognozowania zaburzeń neurologicznych
IL256728A (en) Systems for detecting drugs and autoantibodies against TNF
HRP20181985T1 (hr) Humanizirana protutijela specifična za protofibrilarni oblik beta-amiloidnog peptida
ZA201300519B (en) Novel antibody for the diagnosis and/or prognosis of cancer
IL250691B (en) Anti-ox40 antibodies and methods of using them
SG10201506492PA (en) Improved antibodies of the class igg4
EP2585476A4 (en) ANTIGENS AND ANTIBODIES SPECIFIC TO COLON AND PANCREATIC CANCER
IL220404A (en) Antiseptic antibodies
PT2536764T (pt) Anticorpos humanizados anti-cd28
IL216835A0 (en) Anti-vegf antibodies and their uses
IL217919A0 (en) Humanized anti-cdcp1 antibodies
IL223290A (en) Anti-1α-il antibodies for the treatment of arthritis
ZA201202227B (en) Monoclonal antibodies
IL222198A0 (en) Humanized anti cxcr4 antibodies for the treatment of cancer
IL221184A (en) A process for preparing 1-alkylated tetrazole 5 is produced
PL387227A1 (pl) Sposób kompletowania wkładu albumowego
HK1175245A (en) Assays for the detection of anti-tnf drugs and autoantibodies